AzTrials
AzTrials

Gastric NeoplasmNCT06495645

Miss Rate of Gastric Neoplasms Under Computer-aided Endoscopy

A study testing AI-assisted upper gastrointestinal endoscopy in people with Gastric Neoplasm and Artificial Intelligence, run by The University of Hong Kong at 1 site in Hong Kong.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This prospective randomized trial compares AI-assisted upper gastrointestinal endoscopy with high definition upper gastrointestinal endoscopy in term of missed rate of gastric neoplasm. Read more about this study

Who is it for?
Ages 40 years and older
Conditions the study is for
Gastric Neoplasm, Artificial Intelligence
What is being tested?
AI-assisted upper gastrointestinal endoscopy
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,000 participants
Where
1 siteHong Kong
Study dates
1 Nov 2024to 31 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients aged 40 or older
  • Scheduled for elective upper endoscopy

Who cannot join

  • Pregnant women,
  • Inability to provide written informed consent
  • Prior gastrectomy, and
  • Patients deemed unsuitable or high-risk for endoscopy with severe comorbid illnesses

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Thomas Ka-Luen Lui contact

+852 97360997

tkllui@hku.hk

Hong Kong1 site, 1 recruiting
  • Queen Mary Hospital, the University of Hong Kong

    Hong Kong

    Thomas Ka Luen Lui, +852 97360997, tkllui@hku.hk

    Recruiting

Other trials in Hong Kong

About this study

Official title: Computer-aided Gastric Lesion Localization and Miss Rate of Gastric Neoplasms: a Tandem, Randomized Controlled Study

This prospective randomized trial compares AI-assisted upper gastrointestinal endoscopy with high definition upper gastrointestinal endoscopy in term of missed rate of gastric neoplasm. The investigators hypothesize the miss rate of high definition upper gastrointestinal endoscopy is higher than AI-assisted upper gastrointestinal endoscopy.

Read the detailed description

Patients will be randomly assigned to begin with AI-assisted upper gastrointestinal endoscopy follow immediately by high definition (HD) upper gastrointestinal endoscopy (AI-HD group); or start with HD upper gastrointestinal endoscopy follow immediately by AI-assisted upper gastrointestinal endoscopy (HD-AI group). The random allocation sequence is generated by a computer-generated random numerical series, with 1 representing the AI-HD group and 0 representing the HD-AI group. Randomization is conducted in blocks of four at a 1:1 ratio stratified by indications (screening/surveillance vs others), endoscopist's experience (experienced versus less experienced) and mode of sedation (unsedated vs sedated). Experienced endoscopist is defined as qualified endoscopists with more than 7 years experience in upper endoscopy, whereas less experienced endoscopists include fellows and trainees. A research assistant, not directly involved in this study, maintained all randomization codes which are contained within individual opaque envelopes. Upon obtaining patient consent, the envelope will be opened to reveal the assigned examination sequence. Patients remain blinded to their group allocation throughout the study, but the performing endoscopist is aware of the assigned allocation.

Participating endoscopists will receive training on the interpretation of real-time AI detection system as well as detection of dysplasia under HD endoscopy before performing study. All patients will fast for at least 6 hours before the procedure. All examinations will be performed with HD endoscopes (ELUXEO 7000 video system, Fujifilm Co, Tokyo, Japan) under white light. The artificial intelligence assisted gastric dysplasia localization system uses a graphical user interface for real-time display of lesion detection with bounding boxes (Fujifilm Co, Tokyo, Japan).

Each eligible patient will undergo a same-day tandem upper gastrointestinal endoscopy performed by the same endoscopist to evaluate the miss rate of gastric neoplasm. Patients first receive either AI-assisted or HD upper gastrointestinal endoscopy under white light endoscopy, immediately followed by cross-over to other procedure. Endoscopists will be assisted by a research assistant (RS), who activates or deactivates the lesion detection function of AI system between the two examinations. Both first and second examinations are conducted in accordance with the systematic gastric screening protocol, and only the gastric cavity was rescanned during the second observation. The minimal inspection time of the stomach should be 3 minute for the both examination.

Biopsies of all targeted lesions will be taken at the end of each examination. Endoscopists are instructed to biopsy lesions meeting the following criteria in HD examinations: color differences, loss of vascularity, slight elevation or depression, nodularity, thickening, abnormal convergence or flattening of folds, irregular margins, irregular discoloration, or irregular surface. During AI-assisted examinations, targeted lesions are defined as focal lesions marked in localization boxes. Endoscopists are instructed to biopsy areas stably marked with localization boxes that persisted for 5 seconds by the AI system.

Being tested
AI-assisted upper gastrointestinal endoscopy
Keywords
Gastric Neoplasm, Artificial intelligence, Miss rate
Medical subject headings
Stomach Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AI-assisted upper gastrointestinal endoscopyDevice

    AI-assisted upper gastrointestinal endoscopy

Study groups in NCT06495645
Study groupRoleWhat they receive
AI-HD groupExperimentalAI-assisted upper gastrointestinal endoscopy follow immediately by high definition (HD) upper gastrointestinal endoscopy
Receives: Device: AI-assisted upper gastrointestinal endoscopy
HD-AI groupActive comparatorHD upper gastrointestinal endoscopy follow immediately by AI-assisted upper gastrointestinal endoscopy
Receives: Device: AI-assisted upper gastrointestinal endoscopy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gastric neoplasia miss rate

    the number of newly detected gastric neoplasia in the second examination divided by the total number of gastric neoplasia detected in both examinations for each patient.

    Measured: during the intervention

Secondary outcomes (9)
  1. Gastric neoplasia detection rate

    The proportion of patients with one or more gastric neoplasms detected in the first examination

    Measured: during the intervention

  2. The biopsy rate

    The proportion of patients who had a biopsy sample taken as a result of the first examination

    Measured: during the intervention

  3. The number of gastric neoplasms per patient

    The total number of gastric neoplasms detected in the first examination divided by the total number of patients

    Measured: during the intervention

  4. The miss rate of patients with gastric neoplasms

    The number of patients with a newly detected gastric neoplasm in the second examination divided by the total number of patients with gastric neoplasms detected in both examinations

    Measured: during the intervention

  5. The positive predictive value (PPV) for gastric neoplasms

    The number of detected gastric neoplasms divided by the number of all targeted lesions in the first examination

    Measured: during the intervention

  6. Inspection time

    The procedure time of the examinations minus the time taken to obtain a biopsy sample, measured from the passage of the endoscope through the gastroesophageal junction until the completion of the whole examination of the gastric cavity, excluding the inspection time of the duodenum and the biopsy time

    Measured: during the intervention

  7. The macroscopic and histological types of detected and missed neoplasia in the first examination

    The macroscopic and histological types of detected and missed neoplasia in the first examination

    Measured: during the intervention

  8. Number of biopsy per patient in the first arm

    Number of biopsy per patient in the first arm

    Measured: during the intervention

  9. Percentage of positive biopsy

    The number of gastric neoplasm detected divided by total number of biopsy in the first arm

    Measured: during the intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jul 2024
  2. Study start1 Nov 2024
  3. Primary completion1 Sep 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06495645
Sponsor's protocol ID
protocol_upper_RCTV10
Status last verified
Nov 2025
First submitted
25 Jun 2024
Last updated
20 Nov 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing AI-assisted upper gastrointestinal endoscopy in people with Gastric Neoplasm and Artificial Intelligence, run by The University of Hong Kong at 1 site in Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 20 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Thomas Ka-Luen Lui (+852 97360997, tkllui@hku.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gastric neoplasia miss rate (time frame: during the intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in